Neurology

Fosdenopterin (Nulibry) is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency Type A.

Haloperidol (Haldol) is indicated for use in the treatment of schizophrenia and to control the symptoms of Tourette's disorder, as well as severe behavioral problems or hyperactivity in children.

Eptinezumab is a calcitonin gene-related peptide antagonist FDA-approved for the preventive treatment of migraine.

Dhivy is a levodopa/carbidopa combination formulation approved by the FDA in November 2021 for the treatment of Parkinson disease or manifestations due to viral or environmental exposures.

Ponesimod (Ponvory) is indicated for the treatment of relapsing forms of multiple sclerosis.

Pharmacists should review the medications of patients with multiple sclerosis regularly to assess drug-drug interactions.

Ravulizumab-cwvz (Ultomiris) produced statistically significant improvements in measures of functional activity, muscle strength, and quality of life in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

Pharmacists who educate patients with multiple sclerosis and expand their understanding and knowledge of the condition empowers them to take part in a more active role in managing their health.

Valbenazine (Ingrezza) is indicated for the treatment of adults with tardive dyskinesia.

New validated testing method for multiple sclerosis measures kappa immunoglobulin free light chains in cerebrospinal fluid.

Namzaric is indicated for the treatment of moderate to severe dementia related to Alzheimer disease.

Donepezil (Aricept) is an acetylcholinesterase inhibitor indicated for the treatment of dementia related to Alzheimer disease.

Phase 3 trial results also indicate that Alzheimer disease clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks.

Corium’s Adlarity system lowers the likelihood of adverse gastrointestinal (GI) events that are normally associated with the oral medication.

Individuals with multiple sclerosis should follow vaccine guidelines before starting disease-modifying therapies, case study results show.

Michael Abrams, MPH, PhD, senior health researcher at Public Citizen’s Health Research Group, discusses whether classification of gabapentin as schedule V would end patients’ access to the drug.

Pharmacists hold a vastly underrecognized role within the care team—a role that offers a unique approach toward the therapeutic management of rare diseases.

Diroximel fumarate (Vumerity) is indicated for the treatment of relapsing forms of multiple sclerosis.

The agency has also approved the baclofen oral suspension for Azurity Pharmaceuticals to treat individuals with other spinal cord diseases or injuries.

Many people who experience a grand mal seizure never have another one and don't need treatment.

Gliomas begin in the glial cells that surround nerve cells and help them function.

The researchers projected that approximately 14 participants would experience a significant worsening of their walking function, however, only 8 participants had their walking function decline.

Agency green light could help get medication off ASHP drug shortage list by reducing supply issues.

Study results suggest that infection with Epstein-Barr virus may be the leading cause of multiple sclerosis.

Somapacitan (Sogroya; Novo Nordisk) injection is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

Study data showed that increased levels of infection, inflammation, and metabolic alterations frequently observed in people with depression and psychosis may be a cause rather than a consequence of these disorders.

New study results show that though men are more likely to have heart conditions, the impact on their memory and thinking skills is lower.

Generalized anxiety disorder has symptoms that are similar to panic disorder, obsessive-compulsive disorder, and other types of anxiety.

The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors.

This is an update to the 2011 AAN guideline on the treatment of painful diabetic neuropathy, according to a press release.